A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
A Randomized Open-Label Multicenter Phase III Clinical Trial Comparing JS203 Combined With gemcitabine plus oxaliplatin (JS203-GemOx) Versus rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age range: 18 to 75 years old (inclusive), both male and female are acceptable
ECOG: 0-1;
One of the confirmed histologies below with CD20-positivity:
DLBCL, not otherwise specified (NOS), including de novo or histologically transformed from follicular lymphoma (FL)/Marginal Zone Lymphoma(MZL) "Double-hit" or "triple-hit" DLBCL , including de novo or histologically transformed from FL/MZL FL Grade 3B T-cell/histiocyte-rich large B-cell lymphoma
At least one measurable lesion meeting the criteria specified in the Lugano 2014 response assessment;
Acceptable organ function at screening;
You may not be if
A history of severe allergy to monoclonal antibody therapy (or recombinant antibody-related fusion protein);
Previously received CD20-CD3 bispecific antibody treatment;